These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12938866)

  • 1. Neurobiology of bipolar illness: implications for future study and therapeutics.
    Post RM; Speer AM; Hough CJ; Xing G
    Ann Clin Psychiatry; 2003 Jun; 15(2):85-94. PubMed ID: 12938866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mood stabilizers--past, present and future].
    Sümegi A
    Neuropsychopharmacol Hung; 2008 Mar; 10(1):31-42. PubMed ID: 18771018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neuropatological and neurochemical abnormalities in bipolar disorder].
    Frey BN; Fonseca MM; Machado-Vieira R; Soares JC; Kapczinski F
    Braz J Psychiatry; 2004 Sep; 26(3):180-8. PubMed ID: 15645064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. White matter alterations in bipolar disorder: potential for drug discovery and development.
    Marlinge E; Bellivier F; Houenou J
    Bipolar Disord; 2014 Mar; 16(2):97-112. PubMed ID: 24571279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures.
    Post RM; Weiss SR
    Mol Neurobiol; 1996 Aug; 13(1):33-60. PubMed ID: 8892335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signaling: cellular insights into the pathophysiology of bipolar disorder.
    Manji HK; Lenox RH
    Biol Psychiatry; 2000 Sep; 48(6):518-30. PubMed ID: 11018224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers.
    Gould TD; Quiroz JA; Singh J; Zarate CA; Manji HK
    Mol Psychiatry; 2004 Aug; 9(8):734-55. PubMed ID: 15136794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients.
    Moore GJ; Cortese BM; Glitz DA; Zajac-Benitez C; Quiroz JA; Uhde TW; Drevets WC; Manji HK
    J Clin Psychiatry; 2009 Apr; 70(5):699-705. PubMed ID: 19389332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can brain-imaging studies provide a 'mood stabilizer signature?'.
    Soares JC
    Mol Psychiatry; 2002; 7 Suppl 1():S64-70. PubMed ID: 11986997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contributions from brain imaging to the elucidation of pathophysiology of bipolar disorder.
    Soares JC
    Int J Neuropsychopharmacol; 2003 Jun; 6(2):171-80. PubMed ID: 12890310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional cerebral glucose metabolic abnormalities in bipolar II depression.
    Mah L; Zarate CA; Singh J; Duan YF; Luckenbaugh DA; Manji HK; Drevets WC
    Biol Psychiatry; 2007 Mar; 61(6):765-75. PubMed ID: 17027930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness.
    Manji HK; Moore GJ; Chen G
    Biol Psychiatry; 2000 Oct; 48(8):740-54. PubMed ID: 11063971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The place of anticonvulsant therapy in bipolar illness.
    Post RM; Ketter TA; Denicoff K; Pazzaglia PJ; Leverich GS; Marangell LB; Callahan AM; George MS; Frye MA
    Psychopharmacology (Berl); 1996 Nov; 128(2):115-29. PubMed ID: 8956373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropathology of bipolar disorder.
    Vawter MP; Freed WJ; Kleinman JE
    Biol Psychiatry; 2000 Sep; 48(6):486-504. PubMed ID: 11018222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications.
    Manji HK; Bebchuk JM; Moore GJ; Glitz D; Hasanat KA; Chen G
    J Clin Psychiatry; 1999; 60 Suppl 2():27-39; discussion 40-1, 113-6. PubMed ID: 10073385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of Wnt signaling and its interaction with diverse mechanisms of cellular apoptosis in the pathophysiology of bipolar disorder.
    Hu LW; Kawamoto EM; Brietzke E; Scavone C; Lafer B
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):11-7. PubMed ID: 20828594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The functional neuroanatomy of bipolar disorder: a review of neuroimaging findings.
    Strakowski SM; Delbello MP; Adler CM
    Mol Psychiatry; 2005 Jan; 10(1):105-16. PubMed ID: 15340357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder.
    Lan MJ; McLoughlin GA; Griffin JL; Tsang TM; Huang JT; Yuan P; Manji H; Holmes E; Bahn S
    Mol Psychiatry; 2009 Mar; 14(3):269-79. PubMed ID: 18256615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A microarray gene expression study of the molecular pharmacology of lithium carbonate on mouse brain mRNA to understand the neurobiology of mood stabilization and treatment of bipolar affective disorder.
    McQuillin A; Rizig M; Gurling HM
    Pharmacogenet Genomics; 2007 Aug; 17(8):605-17. PubMed ID: 17622937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain?
    Lenox RH; McNamara RK; Watterson JM; Watson DG
    J Clin Psychiatry; 1996; 57 Suppl 13():23-31; discussion 32-3. PubMed ID: 8970502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.